RxSpan MD NAD+ prices
3 figures read September 2026.
RxSpan MD publishes $199–$249 for NAD+ as a first-period price and never says what it charges afterwards, which makes the headline number the least useful kind of figure in this index for working out what a year costs.
What RxSpan MD publishes
RxSpan MD publishes only a first-month or first-order price, and never says what it charges afterwards. Of the 3 sellers in this index that fall in the same bucket, that puts it with the 3% of the roster that publishes this shape of number rather than another one. A standing rate charged on a calendar month is the only figure this site treats as a monthly price, and 60 of the 106 sellers in this index — including this one — do not publish one.
The figure above is a first period only, “(For the first month)”. This site never prints a price without that qualifier, on any surface, because the same number means a different thing depending on it — and in this corpus the same seller often prints several.
Every figure RxSpan MD publishes — 3 figures, read September 2026
| Figure | What it is | Cycle, in their words | Route | Dose | Read |
|---|---|---|---|---|---|
| $249 | first period | “(For the first month)” | not stated | Not stated | September 2026behind a form |
| $249 | first period | “(For the first month)” | Nasal | Not stated | September 2026behind a form |
| $199 | first period | “(For the first month)” | Oral | Not stated | September 2026behind a form |
In RxSpan MD’s own words
- $249 first period
The page says: “Nicotinamide Adenine Dinucleotide ( NAD+ ) Injection $249 (For the first month)”
Product name says Injection but no administration route (SubQ / IM / IV) is stated anywhere on the page, so route is unspecified. The cycle wording is explicitly first-month only; the wizard's plan step shows $249/mo as the 'Monthly' tier and lower tiers for longer commitments, but that step is not tied to this product in the captured text.
Read from https://www.rxspanmd.com/category/longevity on September 2026.
- $249 first period
The page says: “Nicotinamide Adenine Dinucleotide ( NAD+ ) Nasal Spray $249 (For the first month)”
Same first-month figure as the injection.
Read from https://www.rxspanmd.com/category/longevity on September 2026.
- $199 first period
The page says: “Nicotinamide Adenine Dinucleotide ( NAD+ ) Flex Dose Tablet $199 (For the first month)”
An oral/tablet form of NAD+ itself — the page names it Nicotinamide Adenine Dinucleotide, not NMN or NR — so molecule is NAD+ and the route enum has no tablet value; recorded unspecified. 'Flex Dose' is the product name, not a stated strength.
Read from https://www.rxspanmd.com/category/longevity on September 2026.
Price disclosure score: 57 of 100
This scores what RxSpan MD publishes about its price, and nothing else. It is not a rating of the product, the clinic, the prescriber or the value — this site has read a price page, not used a product. Across all 106 sellers in the index the scores run from 6 to 100, with a median of 72. RxSpan MD sits 87 of 106.
| What is scored | What RxSpan MD publishes | Points |
|---|---|---|
| An exact figure | The published figure is a first-period price. What the seller charges afterwards is not on the page. | 12of 30 |
| A stated cadence | A cadence is stated, but it is a first period or a per-unit price rather than the standing charge. | 10of 20 |
| Visible on the page | Every headline figure (3 figures) is printed where a reader can see it. | 20of 20 |
| A stated route | The seller states how the product is administered, in its own sentence. | 15of 15 |
| A stated dose | None of this seller's 3 figures states a dose, so no cost per milligram can be worked out from the page. | 0of 15 |
| Price disclosure score | This scores what the seller publishes about its price — not the product, the clinic, the prescriber or the value. | 57of 100 |
What RxSpan MD does not publish
Each of these is a count over what was actually read, not an impression. 3 figures were read from this seller, and every sentence below is measured against that number.
- None of the 3 figures read from this seller is a standing rate charged by the calendar month.
- No dose is stated beside any of the 3 figures, so nothing on the page divides into a cost per milligram.
- 3 of 3 figures sit behind a form, a login or an intake, so a reader does not meet them on the way in.
Figures visible to a reader on the seller’s page
3 of 3
Figures stating a dose
0 of 3
Figures that resolve to a usable price
3 of 3
Source: Counted over the 3 figures read from RxSpan MD’s own pages, September 2026. Each track is that figure count.
Where RxSpan MD sits
32 other sellers in this index also state a Nasal and Oral route. Ranked with them on price disclosure, RxSpan MD is 30 of 33. That is a statement about how completely each one publishes a price, and about nothing else — the figures behind those rows are different kinds of number and several of them state no dose, so they are not a like-for- like price comparison and this site does not present them as one.
Boards RxSpan MD appears on
The reading record
This site has read RxSpan MD once, in September 2026. A movement can only be shown between two readings taken here, so there is nothing to show yet — and a single reading is a fact about this site's record, never a statement that the seller held its price.
Figures are read from RxSpan MD’s own public pages and recorded with the date. What counts as a price, and why a “from” figure is recorded as a floor rather than a rate, is set out on the editorial policy page. Prices in this category move quietly, so the figure above is what the page said on September 2026 and not a promise about today.